Sana Biotechnology Inc (SANA)
10.04
+0.04
(+0.40%)
USD |
NASDAQ |
May 07, 16:00
10.04
0.00 (0.00%)
After-Hours: 20:00
Sana Biotechnology Enterprise Value: 1.999B for May 6, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 06, 2024 | 1.999B |
| May 03, 2024 | 2.096B |
| May 02, 2024 | 1.951B |
| May 01, 2024 | 1.918B |
| April 30, 2024 | 1.779B |
| April 29, 2024 | 1.796B |
| April 26, 2024 | 1.717B |
| April 25, 2024 | 1.669B |
| April 24, 2024 | 1.686B |
| April 23, 2024 | 1.578B |
| April 22, 2024 | 1.543B |
| April 19, 2024 | 1.472B |
| April 18, 2024 | 1.499B |
| April 17, 2024 | 1.616B |
| April 16, 2024 | 1.649B |
| April 15, 2024 | 1.680B |
| April 12, 2024 | 1.770B |
| April 11, 2024 | 1.858B |
| April 10, 2024 | 1.779B |
| April 09, 2024 | 1.854B |
| April 08, 2024 | 1.799B |
| April 05, 2024 | 1.781B |
| April 04, 2024 | 1.671B |
| April 03, 2024 | 1.814B |
| April 02, 2024 | 1.739B |
| Date | Value |
|---|---|
| April 01, 2024 | 2.026B |
| March 28, 2024 | 1.999B |
| March 27, 2024 | 1.999B |
| March 26, 2024 | 1.880B |
| March 25, 2024 | 1.799B |
| March 22, 2024 | 1.812B |
| March 21, 2024 | 1.812B |
| March 20, 2024 | 1.768B |
| March 19, 2024 | 1.702B |
| March 18, 2024 | 1.759B |
| March 15, 2024 | 1.752B |
| March 14, 2024 | 1.790B |
| March 13, 2024 | 1.966B |
| March 12, 2024 | 1.838B |
| March 11, 2024 | 1.889B |
| March 08, 2024 | 1.889B |
| March 07, 2024 | 1.907B |
| March 06, 2024 | 1.940B |
| March 05, 2024 | 1.957B |
| March 04, 2024 | 1.880B |
| March 01, 2024 | 2.279B |
| February 29, 2024 | 2.008B |
| February 28, 2024 | 2.147B |
| February 27, 2024 | 1.986B |
| February 26, 2024 | 1.658B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
122.67M
Minimum
Dec 27 2022
7.771B
Maximum
Feb 10 2021
1.555B
Average
872.50M
Median
Enterprise Value Benchmarks
| Rocket Pharmaceuticals Inc | 1.727B |
| Solid Biosciences Inc | 253.83M |
| Dyne Therapeutics Inc | 1.842B |
| Taysha Gene Therapies Inc | 386.56M |
| Tenaya Therapeutics Inc | 253.39M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -88.12M |
| Total Expenses (Quarterly) | 90.62M |
| EPS Diluted (Quarterly) | -0.45 |
| Earnings Yield | -14.64% |